Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for acute congestive heart failure

Sandra Chaparro; Howard C Dittrich; Wh Wilson Tang

doi:10.2217/14796678.4.2.117

Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for acute congestive heart failure

Sandra Chaparro
, Howard C Dittrich
, Wh Wilson Tang

Research output: Contribution to journal › Article › peer-review

Abstract

Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.

Original language	English
Pages (from-to)	117-23
Number of pages	7
Journal	Future cardiology
Volume	4
Issue number	2
DOIs	https://doi.org/10.2217/14796678.4.2.117
State	Published - Mar 2008
Externally published	Yes

Access to Document

10.2217/14796678.4.2.117

Cite this

@article{76a289503dd24fffbf43af9d805f0e1a,

title = "Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for acute congestive heart failure",

abstract = "Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.",

author = "Sandra Chaparro and Dittrich, \{Howard C\} and Tang, \{Wh Wilson\}",

year = "2008",

month = mar,

doi = "10.2217/14796678.4.2.117",

language = "English",

volume = "4",

pages = "117--23",

journal = "Future cardiology",

issn = "1479-6678",

number = "2",

}

TY - JOUR

T1 - Rolofylline (KW-3902)

T2 - a new adenosine A1-receptor antagonist for acute congestive heart failure

AU - Chaparro, Sandra

AU - Dittrich, Howard C

AU - Tang, Wh Wilson

PY - 2008/3

Y1 - 2008/3

N2 - Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.

AB - Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.

U2 - 10.2217/14796678.4.2.117

DO - 10.2217/14796678.4.2.117

M3 - Article

C2 - 19804290

SN - 1479-6678

VL - 4

SP - 117

EP - 123

JO - Future cardiology

JF - Future cardiology

IS - 2

ER -